Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia
The Medicines Intelligence Centre of Research Excellence: co-creating real-world evidence to support the evidentiary needs of Australian regulators and payers